Gil Karen M, Frasure Heidi E, Hopkins Michael P, Jenison Eric L, von Gruenigen Vivian E
Department of Obstetrics and Gynecology, Akron General Medical Center, 224 West Exchange Street, Akron, OH 44302, USA.
Gynecol Oncol. 2006 Oct;103(1):247-52. doi: 10.1016/j.ygyno.2006.03.005. Epub 2006 May 11.
To prospectively examine body weight changes in women with newly diagnosed ovarian cancer receiving surgery and adjuvant chemotherapy. Body composition was examined in a subset of these women.
Body weight (BW) and body composition, using bioelectrical impedance (RJL Systems Inc.), were prospectively measured pre- and post-operatively, and at 3, 6, and 12 months.
Mean age of 42 women was 59 years and did not differ by stage of disease. Nine women with early stage disease did not receive adjuvant chemotherapy. Mean BW of 33 patients receiving chemotherapy decreased from the pre- to post-operative visit and then returned to baseline levels by 12 months (F = 8.70, P = 0.003). Nine patients who did not receive chemotherapy demonstrated a similar pattern (F = 7.0, P = 0.002). Women receiving chemotherapy with stage I/II cancer had a 2.8 +/- 2.0 kg weight gain over the year, and women with stage III/IV cancer had a 1.5 +/- 1.5 kg weight loss (t = 1.72, P = 0.096). A subset of women with stage I/II (n = 6) and stage III/IV (n = 6) ovarian cancer receiving chemotherapy had body composition measured at three time points. Absolute body fat changes paralleled changes in BW (F = 9.95, P = 0.002).
Our study is the first prospective evaluation of body weight and composition in women undergoing surgery and chemotherapy for ovarian cancer. These results demonstrate that women undergoing surgery for ovarian cancer lost weight following surgery and regained it slowly over the following year. Further investigations of weight changes during adjuvant chemotherapy are indicated to assess potential changes in different stages of disease.
前瞻性研究新诊断的卵巢癌女性患者在接受手术及辅助化疗期间的体重变化。并对其中一部分女性患者的身体成分进行检测。
采用生物电阻抗法（RJL Systems Inc.）前瞻性地测量了患者手术前后以及术后3个月、6个月和12个月时的体重（BW）和身体成分。
42名女性的平均年龄为59岁，各疾病分期之间无差异。9名早期疾病患者未接受辅助化疗。33名接受化疗的患者的平均体重在术前至术后访视期间下降，然后在12个月时恢复至基线水平（F = 8.70，P = 0.003）。9名未接受化疗的患者呈现出类似的模式（F = 7.0，P = 0.002）。I/II期癌症且接受化疗的女性在这一年中体重增加了2.8±2.0千克，而III/IV期癌症女性体重减轻了1.5±1.5千克（t = 1.72，P = 0.096）。对一部分I/II期（n = 6）和III/IV期（n = 6）接受化疗的卵巢癌女性在三个时间点测量了身体成分。绝对体脂变化与体重变化平行（F = 9.95，P = 0.002）。
我们的研究是首次对接受卵巢癌手术和化疗的女性的体重和身体成分进行前瞻性评估。这些结果表明，接受卵巢癌手术的女性在术后体重下降，并在随后的一年中缓慢恢复。有必要进一步研究辅助化疗期间的体重变化，以评估疾病不同阶段的潜在变化。
